In August, Swiss pharmaceutical company Rochethat it was entering a collaboration and license agreement with California-based Poseida to develop treatments for hematologic malignancies, or cancers that affect blood, bone marrow, and lymph nodes. The deal offered Poseida a $110 million payment, with up to an additional $110 million pending future milestones.
Cantor Fitzgerald analysts said those deals signal good news for smaller companies that offer similar valuable assets. They named three companies in particular that they said are"fundamentally undervalued" and could be ripe for a takeout:
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: